Praxiszentrum St. Bonifatius

Industry / private company


Location: München, Germany (DE) DE

ISNI: -


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial (2021) Tascilar K, Hagen M, Kleyer A, Simon D, Reiser M, Hueber A, Manger B, et al. Journal article Entwicklung von Qualitätsstandards für die Versorgung von Patient*innen mit rheumatoider Arthritis zur Anwendung in Deutschland (2021) Kiltz U, Buschhorn-Milberger , Albrecht K, Lakomek HJ, Lorenz HM, Rudwaleit M, Schneider M, et al. Journal article New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II study (2019) Englbrecht M, Alten R, Aringer M, Baerwald CG, Burkharde H, Eby N, Flacke JP, et al. Journal article LOOSING DAS28-ESR, BUT STAYING IN BOOLEAN REMISSION-IS IT POSSIBLE? DATA FROM THE PROSPECTIVE, RANDOMISED RETRO TRIAL ON RHEUMATOID ARTHRITIS PATIENTS IN STABLE REMISSION (2018) Erhard J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, et al. Conference contribution Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting (2018) Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll RE, et al. Journal article ELEVATED MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) PREDICTS RELAPSES IN RA PATIENTS IN SUSTAINED REMISSION TAPERING TUMOUR NECROSIS FACTOR INHIBITOR THERAPY-RESULTS FROM THE RANDOMIZED CONTROLLED RETRO STUDY (2017) Rech J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, et al. Conference contribution MULTI-BIOMARKER DISEASE ACTIVITY AND AUTOANTIBODY STATUS LEAD TO COST EFFECTIVE TAPERING ALGORITHMS IN RHEUMATOID ARTHRITIS PATIENTS IN SUSTAINED REMISSION (2017) Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, et al. Conference contribution Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF (2017) Kiltz U, Alten R, Fleck M, Kruger K, Manger B, Nuesslein H, Reuss-Borst M, et al. Journal article Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled Retro- Study (2016) Hagen M, Figueiredo CP, Cobra JF, Haschka J, Reiser M, Englbrecht M, Hueber A, et al. Conference contribution ANTI-MODIFIED PROTEIN ANTIBODY RESPONSE PATTERN INFLUENCES THE RISK FOR DISEASE RELAPSE IN RHEUMATOID ARTHRITIS PATIENTS TAPERING DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (2016) Figueiredo C, Bang H, Cobra JF, Englbrecht M, Hueber AJ, Haschka J, Manger B, et al. Conference contribution